Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

by Jeremie Calais, Johannes Czernin, Wolfgang P. Fendler, David Elashoff, Nicholas G. Nickols
Published 2019-01-01

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

by Jeremie Calais, Johannes Czernin, Wolfgang P. Fendler, David Elashoff, Nicholas G. Nickols
Published 2019-01-01

Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance

by Demetrios N. Simopoulos, Shyam Natarajan, Tonye A. Jones, Wolfgang P. Fendler, Anthony E. Sisk, Jr., Leonard S. Marks
Published 2017-09-01

Imaging Inflammation with Positron Emission Tomography

by Janette Iking, Magdalena Staniszewska, Lukas Kessler, Jasmin M. Klose, Katharina Lückerath, Wolfgang P. Fendler, Ken Herrmann, Christoph Rischpler
Published 2021-02-01

18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis.

by Cornelius Deuschl, Theodor Rüber, Leon Ernst, Wolfgang P Fendler, Julian Kirchner, Christoph Mönninghoff, Ken Herrmann, Carlos M Quesada, Michael Forsting, Christian E Elger, Lale Umutlu
Published 2020-01-01

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

by Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, Jasmin M. Klose, Jasmin Wosniack, Henning Reis, Tibor Szarvas, Boris Hadaschik, Katharina Lückerath, Ken Herrmann, Wolfgang P. Fendler, Janette Iking
Published 2021-07-01

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

by Jeremie Calais, Shaojun Zhu, Nader Hirmas, Matthias Eiber, Boris Hadaschik, Martin Stuschke, Ken Herrmann, Johannes Czernin, Amar U. Kishan, Nicholas G. Nickols, David Elashoff, Wolfgang P. Fendler
Published 2021-05-01

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

by Hubertus Hautzel, Yazan Alnajdawi, Wolfgang P. Fendler, Christoph Rischpler, Kaid Darwiche, Wilfried E. Eberhardt, Lale Umutlu, Dirk Theegarten, Martin Stuschke, Martin Schuler, Clemens Aigner, Ken Herrmann, Till Plönes
Published 2021-07-01

Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension

by Manuel Weber, Ina Binse, Karin Oebbecke, Tim Brandenburg, Ken Herrmann, Sarah Theurer, Frank Weber, Ann-Kathrin Ehrlich, Kurt Werner Schmid, Dagmar Führer-Sakel, Irfan Vardarli, Wolfgang P. Fendler, Elena Gilman, Rainer Görges
Published 2021-08-01

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

by Katharina Lückerath, Liu Wei, Wolfgang P. Fendler, Susan Evans-Axelsson, Andreea D. Stuparu, Roger Slavik, Christine E. Mona, Jeremie Calais, Matthew Rettig, Robert E. Reiter, Ken Herrmann, Caius G. Radu, Johannes Czernin, Matthias Eiber
Published 2018-10-01

Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.

by Ralf S Eschbach, Wolfgang P Fendler, Philipp M Kazmierczak, Marcus Hacker, Axel Rominger, Janette Carlsen, Heidrun Hirner-Eppeneder, Jessica Schuster, Matthias Moser, Lukas Havla, Moritz J Schneider, Michael Ingrisch, Lukas Spaeth, Maximilian F Reiser, Konstantin Nikolaou, Clemens C Cyran
Published 2015-01-01